Taysha Gene Therapies, Inc. (TSHA) Reports Q3 Loss, Lags Revenue Estimates
Portfolio Pulse from
Taysha Gene Therapies, Inc. (TSHA) reported a Q3 loss of $0.09 per share, missing the Zacks Consensus Estimate of a $0.08 loss. This is an improvement from the $0.13 loss per share reported a year ago.
November 13, 2024 | 11:30 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Taysha Gene Therapies reported a Q3 loss of $0.09 per share, missing the consensus estimate of $0.08. Despite missing estimates, the loss is an improvement from the previous year's $0.13 per share.
The reported loss per share of $0.09 was worse than the expected $0.08, which is likely to negatively impact the stock price in the short term. However, the improvement from last year's $0.13 loss may mitigate some negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100